Anorectal Strictures in Complex Perianal CD: How to Approach?

Abstract

Anorectal strictures are a notoriously difficult to treat phenotype of perianal Crohn's disease. Quality of life is diminished due to ongoing pain, incontinence, difficulty with stool evacuation, and recurrent medical and surgical treatments. Medical therapy is aimed at treating luminal disease and mucosal ulceration to prevent worsening of fibrosis. Clinical examination and endoscopic intervention can be used for serial dilations of strictures. Unfortunately, despite optimal medical therapy and endoscopic intervention with serial anal dilations, surgery with intestinal diversion or proctocolectomy may be required as part of the treatment algorithm in a significant proportion of patients.

Keywords

anal canal disease - anal stenosis - proctocolectomy

Publikationsverlauf

Artikel online veröffentlicht:
17. Januar 2022

• References

• 1 Linares L, Moreira LF, Andrews H, Allan RN, Alexander-Williams J, Keighley MR. Natural history and treatment of anorectal strictures complicating Crohn's disease. Br J Surg 1988; 75 (07) 653-655
• 2 Schwartz DA, Loftus Jr EV, Tremaine WJ. et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology 2002; 122 (04) 875-880
• 3 Lightner AL, Kearney D, Giugliano D. et al. Excisional hemorrhoidectomy: safe in patients with Crohn's disease?. Inflamm Bowel Dis 2020; 22: 1154-1158
• 4 McKenna NP, Lightner AL, Habermann EB, Mathis KL. Hemorrhoidectomy and excision of skin tags in IBD: Harbinger of Doom or simply a disease running its course?. Dis Colon Rectum 2019; 62 (12) 1505-1511
• 5 Kotze PG, Shen B, Lightner A. et al. Modern management of perianal fistulas in Crohn's disease: future directions. Gut 2018; 67 (06) 1181-1194
• 6 Hughes LE. Clinical classification of perianal Crohn's disease. Dis Colon Rectum 1992; 35 (10) 928-932
• 7 Yamamoto T, Kotze PG, Spinelli A, Panaccione R. Fistula-associated anal carcinoma in Crohn's disease. Expert Rev Gastroenterol Hepatol 2018; 12 (09) 917-925
• 8 Bouguen G, Siproudhis L, Bretagne JF, Bigard MA, Peyrin-Biroulet L. Nonfistulizing perianal Crohn's disease: clinical features, epidemiology, and treatment. Inflamm Bowel Dis 2010; 16 (08) 1431-1442
• 9 Marshall JK, Irvine EJ. Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Aliment Pharmacol Ther 1995; 9 (03) 293-300
• 10 Andus T, Kocjan A, Müser M. et al; International Salofalk Suppository OD Study Group. Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. Inflamm Bowel Dis 2010; 16 (11) 1947-1956
• 11 Lamet M. A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg Twice daily in patients with active mild-to-moderate ulcerative proctitis. Dig Dis Sci 2011; 56 (02) 513-522
• 12 Watanabe M, Nishino H, Sameshima Y, Ota A, Nakamura S, Hibi T. Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation—a placebo-controlled study. Aliment Pharmacol Ther 2013; 38 (03) 264-273
• 13 Biancone L, Gionchetti P, Blanco GdelV. et al. Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study. Dig Liver Dis 2007; 39 (04) 329-337
• 14 Campieri M, Cottone M, Miglio F. et al. Beclomethasone dipropionate enemas versus prednisolone sodium phosphate enemas in the treatment of distal ulcerative colitis. Aliment Pharmacol Ther 1998; 12 (04) 361-366
• 15 Hanauer SB, Robinson M, Pruitt R. et al. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group. Gastroenterology 1998; 115 (03) 525-532
• 16 Lémann M, Galian A, Rutgeerts P. et al. Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis. Aliment Pharmacol Ther 1995; 9 (05) 557-562
• 17 Mulder CJ, Fockens P, Meijer JW, van der Heide H, Wiltink EH, Tytgat GN. Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. Eur J Gastroenterol Hepatol 1996; 8 (06) 549-553
• 18 Jaeger SU, Klag T, Hoeger K. et al. Tacrolimus suppositories in therapy-resistant ulcerative proctitis. Inflamm Intest Dis 2019; 3 (03) 116-124
• 19 Lawrance IC, Copeland TS. Rectal tacrolimus in the treatment of resistant ulcerative proctitis. Aliment Pharmacol Ther 2008; 28 (10) 1214-1220
• 20 Casson DH, Eltumi M, Tomlin S, Walker-Smith JA, Murch SH. Topical tacrolimus may be effective in the treatment of oral and perineal Crohn's disease. Gut 2000; 47 (03) 436-440
• 21 Hart AL, Plamondon S, Kamm MA. Topical tacrolimus in the treatment of perianal Crohn's disease: exploratory randomized controlled trial. Inflamm Bowel Dis 2007; 13 (03) 245-253
• 22 Stringer EE, Nicholson TJ, Armstrong D. Efficacy of topical metronidazole (10 percent) in the treatment of anorectal Crohn's disease. Dis Colon Rectum 2005; 48 (05) 970-974
• 23 Maeda Y, Ng SC, Durdey P. et al; Topical Metronidazole in Perianal Crohn's Study Group. Randomized clinical trial of metronidazole ointment versus placebo in perianal Crohn's disease. Br J Surg 2010; 97 (09) 1340-1347
• 24 Wallenhorst T, Brochard C, Le Balch E. et al. Anal ulcerations in Crohn's disease: natural history in the era of biological therapy. Dig Liver Dis 2017; 49 (11) 1191-1195
• 25 Ouraghi A, Nieuviarts S, Mougenel JL. et al. Infliximab therapy for Crohn's disease anoperineal lesions. Gastroenterol Clin Biol 2001; 25 (11) 949-956
• 26 Bouguen G, Trouilloud I, Siproudhis L. et al. Long-term outcome of non-fistulizing (ulcers, stricture) perianal Crohn's disease in patients treated with infliximab. Aliment Pharmacol Ther 2009; 30 (07) 749-756
• 27 Brochard C, Siproudhis L, Wallenhorst T. et al. Anorectal stricture in 102 patients with Crohn's disease: natural history in the era of biologics. Aliment Pharmacol Ther 2014; 40 (07) 796-803
• 28 Brady III CE, Cooley BJ, Davis JC. Healing of severe perineal and cutaneous Crohn's disease with hyperbaric oxygen. Gastroenterology 1989; 97 (03) 756-760
• 29 Colombel JF, Mathieu D, Bouault JM. et al. Hyperbaric oxygenation in severe perineal Crohn's disease. Dis Colon Rectum 1995; 38 (06) 609-614
• 30 Shen B, Kochhar G, Navaneethan U. et al; Global Interventional Inflammatory Bowel Disease Group. Role of interventional inflammatory bowel disease in the era of biologic therapy: a position statement from the Global Interventional IBD Group. Gastrointest Endosc 2019; 89 (02) 215-237
• 31 Bemelman WA, Warusavitarne J, Sampietro GM. et al. ECCO-ESCP consensus on surgery for Crohn's disease. J Crohn's Colitis 2018; 12 (01) 1-16
• 32 Schwartz DA, Wiersema MJ, Dudiak KM. et al. A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn's perianal fistulas. Gastroenterology 2001; 121 (05) 1064-1072
• 33 Shen B. interventional IBD: the role of endoscopist in the multidisciplinary team management of IBD. Inflamm Bowel Dis 2018; 24 (02) 298-309
• 34 Galandiuk S, Kimberling J, Al-Mishlab TG, Stromberg AJ. Perianal Crohn disease: predictors of need for permanent diversion. Ann Surg 2005; 241 (05) 796-801 , discussion 801–802
• 35 Burke JP. Role of fecal diversion in complex Crohn's disease. Clin Colon Rectal Surg 2019; 32 (04) 273-279
• 36 Burman JH, Thompson H, Cooke WT, Williams JA. The effects of diversion of intestinal contents on the progress of Crohn's disease of the large bowel. Gut 1971; 12 (01) 11-15
• 37 Harper PH, Kettlewell MG, Lee EC. The effect of split ileostomy on perianal Crohn's disease. Br J Surg 1982; 69 (10) 608-610
• 38 McIlrath DC. Diverting ileostomy or colostomy in the management of Crohn's disease of the colon. Arch Surg 1971; 103 (02) 308-310
• 39 Zelas P, Jagelman DG. Loop illeostomy in the management of Crohn's colitis in the debilitated patient. Ann Surg 1980; 191 (02) 164-168
• 40 Edwards CM, George BD, Jewell DP, Warren BF, Mortensen NJ, Kettlewell MG. Role of a defunctioning stoma in the management of large bowel Crohn's disease. Br J Surg 2000; 87 (08) 1063-1066
• 41 Yamamoto T, Allan RN, Keighley MR. Effect of fecal diversion alone on perianal Crohn's disease. World J Surg 2000; 24 (10) 1258-1262 , discussion 1262–1263
• 42 Régimbeau JM, Panis Y, Cazaban L. et al. Long-term results of faecal diversion for refractory perianal Crohn's disease. Colorectal Dis 2001; 3 (04) 232-237
• 43 Gu J, Valente MA, Remzi FH, Stocchi L. Factors affecting the fate of faecal diversion in patients with perianal Crohn's disease. Colorectal Dis 2015; 17 (01) 66-72
• 44 Singh S, Ding NS, Mathis KL. et al. Systematic review with meta-analysis: faecal diversion for management of perianal Crohn's disease. Aliment Pharmacol Ther 2015; 42 (07) 783-792
• 45 Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther 2006; 23 (08) 1097-1104
• 46 Devon KM, Brown CJ, Burnstein M, McLeod RS. Cancer of the anus complicating perianal Crohn's disease. Dis Colon Rectum 2009; 52 (02) 211-216
• 47 Jess T, Gamborg M, Matzen P, Munkholm P, Sørensen TI. Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol 2005; 100 (12) 2724-2729
• 48 Ogawa H, Haneda S, Shibata C. et al. Adenocarcinoma associated with perianal fistulas in Crohn's disease. Anticancer Res 2013; 33 (02) 685-689
• 49 Thomas M, Bienkowski R, Vandermeer TJ, Trostle D, Cagir B. Malignant transformation in perianal fistulas of Crohn's disease: a systematic review of literature. J Gastrointest Surg 2010; 14 (01) 66-73
• 50 de Buck van Overstraeten A, Wolthuis AM, Vermeire S. et al. Intersphincteric proctectomy with end-colostomy for anorectal Crohn's disease results in early and severe proximal colonic recurrence. J Crohn's Colitis 2013; 7 (06) e227-e231
• 51 Fichera A, McCormack R, Rubin MA, Hurst RD, Michelassi F. Long-term outcome of surgically treated Crohn's colitis: a prospective study. Dis Colon Rectum 2005; 48 (05) 963-969
• 52 Weterman IT, Peña AS. The long-term prognosis of ileorectal anastomosis and proctocolectomy in Crohn's disease. Scand J Gastroenterol 1976; 11 (02) 185-191
• 53 Vender RJ, Rickert RR, Spiro HM. The outlook after total colectomy in patients with Crohn's colitis and ulcerative colitis. J Clin Gastroenterol 1979; 1 (03) 209-217
• 54 Ho I, Greenstein AJ, Bodian CA, Janowitz HD. Recurrence of Crohn's disease in end ileostomies. Inflamm Bowel Dis 1995; 1 (03) 173-178
• 55 Onali S, Petruzziello C, Calabrese E. et al. Frequency, pattern, and risk factors of postoperative recurrence of Crohn's disease after resection different from ileo-colonic. J Gastrointest Surg 2009; 13 (02) 246-252
• 56 Amiot A, Gornet JM, Baudry C. et al. Crohn's disease recurrence after total proctocolectomy with definitive ileostomy. Dig Liver Dis 2011; 43 (09) 698-702
• 57 Lopez J, Konijeti GG, Nguyen DD, Sauk J, Yajnik V, Ananthakrishnan AN. Natural history of Crohn's disease following total colectomy and end ileostomy. Inflamm Bowel Dis 2014; 20 (07) 1236-1241
• 58 Leal-Valdivieso C, Marín I, Mañosa M. et al. Should we monitor Crohn's disease patients for postoperative recurrence after permanent ileostomy?. Inflamm Bowel Dis 2012; 18 (01) E196
• 59 Goligher JC. The long-term results of excisional surgery for primary and recurrent Crohn's disease of the large intestine. Dis Colon Rectum 1985; 28 (01) 51-55
• 60 Adamina M, Bonovas S, Raine T. et al. ECCO guidelines on therapeutics in Crohn's disease: surgical treatment. J Crohn's Colitis 2020; 14 (02) 155-168